![Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on](https://cyberleninka.org/viewer_images/270172/f/1.png)
Efficacy and safety of entacapone in levodopa/carbidopa versus levodopa/benserazide treated Parkinson's disease patients with wearing-off – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on
Public Assessment Report Scientific discussion Levodopa/Carbidopa/Entacapone “Teva B.V.” 50 mg/12.5 mg/200 mg 75 mg/18.75 mg
Foglio illustrativo: informazioni per il paziente Levodopa/Carbidopa/Entacapone Teva 50 mg/12,5 mg/200 mg compresse rivestite co
![EP2656856A2 - Tablet formulation comprising levodopa, carbidopa, entacapone providing extended release - Google Patents EP2656856A2 - Tablet formulation comprising levodopa, carbidopa, entacapone providing extended release - Google Patents](https://patentimages.storage.googleapis.com/ea/0f/a6/eef83c8eacb790/imgb0003.png)
EP2656856A2 - Tablet formulation comprising levodopa, carbidopa, entacapone providing extended release - Google Patents
![Frontiers | The pharmacokinetics of continuous subcutaneous levodopa/ carbidopa infusion: Findings from the ND0612 clinical development program Frontiers | The pharmacokinetics of continuous subcutaneous levodopa/ carbidopa infusion: Findings from the ND0612 clinical development program](https://www.frontiersin.org/files/Articles/1036068/fneur-13-1036068-HTML/image_m/fneur-13-1036068-g001.jpg)